Army enters partnership to create MERS vaccine
The cooperative research and development agreement is specifically to further GLS-5300, the DNA vaccine from GeneOne to prevent MERS. The human trial of this vaccine will be the first for a MERS treatment or vaccine.
"It is very important we seize the opportunity to advance promising MERS vaccine candidates into human trials,” Col. Stephen Thomas, an infectious diseases physician and WRAIR's deputy commander of operations, said. “We want to understand this vaccine's safety and potential to protect as soon as possible. I believe U.S. military personnel could be at risk in the event of a large scale MERS outbreak. For this reason, I am glad we will collaborate with GeneOne to take the next steps in developing this vaccine candidate.”
The trial will be conducted at the Clinical Trials Center for WRAIR.
"We are pleased to collaborate with the world-class clinicians and scientists at Walter Reed Army Institute of Research,” GeneOne CEO Young Park said. “Our partnership with WRAIR will be a catalyst to rapidly advance MERS vaccine development. GeneOne is taking a leading role responding to the MERS health crisis and stands ready to advance other DNA vaccines for challenging infectious diseases."